AOD 9604

How It Works:
AOD 9604 is a modified form of amino acids 176-191 of the GH polypeptide. Investigators at Monash University discovered that the fat-reducing
effects of GH appear to be controlled by a small region near one end of the GH molecule. This region, which consists of amino acids 176-191, is less
than 10% of the total size of the GH Molecule and appears to have no effects on growth or insulin resistance. This hypothesis was proven in animals
to a tremendous degree with specimen losing a significant amount of fat mass. However, in phase three clinical trials the peptide didn’t meet its
confidenc e interval. Instead, it is now being studied for its effect on bone and cartilage. AOD 9604 possesses many other regenerative properties
associated with growth hormones molecule. This region, which consists of amino acids 176-191, is less than 10% of the total size of the GH Molecule
and appears to have no effects on growth or insulin resistance. This hypothesis was proven in animals to a tremendous degree with specimen losing
a significant amount of fat mass. However, in phase three clinical trials the peptide didn’t meet its confidenc e interval. Instead, it is now being studied
for its effect on bone and cartilage. AOD 9604 possesses many other regenerative properties associated with growth hormones.
Key Benefits:
Currently trials are ongoing to show the application of AOD 9604 in osteoarthritis, Hypercholesterolemia, bone and cartilage repair. AOD 9604 has
an excellent safety profile, recently obtaining Human GRAS status in the USA.
Content & Potency:
Injectable
10mg Vial: Reconstitute 5ml with BWFI (2mg/ml – 5ml) Inject 0.25ml subcutaneously